Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics


Intellia Therapeutics, Inc. (NTLA)

Today's Latest Price: $74.36 USD

1.77 (2.44%)

Updated Jan 22 4:00pm

Add NTLA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

NTLA Stock Summary

  • With a price/sales ratio of 68.8, Intellia Therapeutics Inc has a higher such ratio than 95.42% of stocks in our set.
  • Revenue growth over the past 12 months for Intellia Therapeutics Inc comes in at 55.66%, a number that bests 90.66% of the US stocks we're tracking.
  • The volatility of Intellia Therapeutics Inc's share price is greater than that of 95.51% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Intellia Therapeutics Inc are KALV, MTEM, CRBP, NXTC, and DTIL.
  • Visit NTLA's SEC page to see the company's official filings. To visit the company's web site, go to www.intelliatx.com.

NTLA Stock Price Chart Interactive Chart >

Price chart for NTLA

NTLA Price/Volume Stats

Current price $74.36 52-week high $92.00
Prev. close $72.59 52-week low $9.18
Day low $70.33 Volume 1,961,800
Day high $75.69 Avg. volume 2,003,157
50-day MA $53.57 Dividend yield N/A
200-day MA $28.55 Market Cap 4.39B

Intellia Therapeutics, Inc. (NTLA) Company Bio


Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


NTLA Latest News Stream


Event/Time News Detail
Loading, please wait...

NTLA Latest Social Stream


Loading social stream, please wait...

View Full NTLA Social Stream

Latest NTLA News From Around the Web

Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

Yahoo | January 20, 2021

7 CRISPR Stocks for the Future of Medicine

In June 2012, the world changed forever. You probably didn’t even notice. It was in that month’s issue of the Science journal that U.C. Berkeley professor Jennifer Doudna and Umea University professor Emmanuelle Charpentier unveiled what the scientific community has since labeled the “scientific breakthrough of the century.” The breakthrough: CRISPR-Cas9 genetic editing systems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Doudna and Charpentier invented a pair of “scissors” – called CRISPR-Cas9 systems – to cut specific DNA threads and modify genes inside of living organisms. How? Bacteria. Doudna and Charpentier noted a naturally occurring genome editing system in bacteria, wherein bacteria capture snippets of DNA from invading viruses and create new DNA segments call...

Yahoo | January 15, 2021

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

Yahoo | January 11, 2021

Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Raymond James Stick to Their Buy Rating for Intellia Therapeutics

Investing.com | January 8, 2021

CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

Yahoo | January 8, 2021

Read More 'NTLA' Stories Here

NTLA Price Returns

1-mo 19.67%
3-mo 198.87%
6-mo 271.24%
1-year 438.84%
3-year 235.86%
5-year N/A
YTD 36.69%
2020 270.82%
2019 7.47%
2018 -28.98%
2017 46.61%
2016 N/A

Continue Researching NTLA

Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:

Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.801 seconds.